USANA Health Sciences, Inc.

USANA Health Sciences, Inc. (USNA) is currently trading at $18.88, with a 52-week range of $16.6 to $38.32. Reaching the $23 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $39.0 for USANA Health Sciences, Inc., with a Hold rating, and the most bullish analysts see the stock reaching as high as $39.0. Whether USANA Health Sciences, Inc. can reach $23 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Consumer Defensive space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the USNA Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Whether USANA Health Sciences, Inc. (USNA) is worth buying at $18.88 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: USANA Health Sciences, Inc. trades at a Price-to-Earnings (P/E) ratio of 37.8x, which can be compared against other Consumer Defensive companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency:

Financial health: The Debt-to-Equity ratio of 2.35 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for USNA is currently Hold, with a mean price target of $39.0 based on 1 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

As of 2026, Wall Street analysts have set a consensus (mean) price target of $39.0 for USANA Health Sciences, Inc. (USNA), aggregated from 1 analyst ratings. The overall analyst recommendation is Hold.

The price target range spans from $39.0 on the bearish end to $39.0 on the most optimistic projection, with a median target of $39.0. This wide range reflects differing views on USANA Health Sciences, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the USNA analysis page on StockSifting.

USANA Health Sciences, Inc. (USNA) currently has a Price-to-Earnings (P/E) ratio of 37.8x, meaning investors are paying $37.8 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Consumer Defensive sector tends to command higher valuation multiples when growth expectations are elevated. A 37.8x P/E is on the higher end, suggesting the market is pricing in continued strong earnings growth — any disappointment in future earnings could lead to a multiple contraction.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of USNA's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

Projecting USANA Health Sciences, Inc. (USNA)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the USNA Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.